Healthcare-Associated Infection Assay Launches in Europe

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), recently announced that it obtained CE Marking for the BD MAX™ MRSA Assay to rapidly and accurately identify methicillinresistant Staphylococcus aureus (MRSA) in patients. Rapid and accurate information enables infection control measures to be implemented faster which can positively impact patient management.

“When we launched BD MAX earlier this year, our goal was to provide a next-generation molecular testing system designed to accommodate a broad range of assays that laboratories want and need,” said Tom Polen, President, BD Diagnostics – Diagnostic Systems.

“As the first healthcare-associated infection assay developed by BD for use on the BD MAX System, this milestone represents further confirmation of the potential of this fully-automated system. This systemenables laboratories to offer a broad range of molecular tests that meet both their current andfuture clinical needs.”

BD MAX is the first and only fully automated, bench-top molecular system designed to perform a broad range of molecular testing. This offers laboratory professionals the flexibility and versatility to perform CE/in vitro diagnostic (IVD) assays and user defined protocols on the same platform.

The dual functionality of open system and CE/IVD capabilities on the BD MAX System enables laboratories to consolidate a broad range of molecular tests on a single workstation. This flexibility provides clinicians with the best information to make critical treatment and management decisions to improve patient care.

According to Polen, BD plans to build on the successful launch of the BD MAX MRSA Assay by developing additional assays for the BD MAX System for a broad range of disease categories. There are now more than 20 assays in the BD MAX System’s content-rich menu pipeline.